Kornimate/medical-research-clean huggingface dataset:
post-stroke depression treatment effect on stroke recurrence

Conditions: Stroke Recurrence; Cardiovascular Events; Depression

Summary: it is not clear whether depresssion can predispose, or precipitate stroke recurrence in patients with stroke. we sought the relationship of post stroke depression with stroke recurrence.

a large body of evidence suggests that depression is associated with a increased risk of many chronic diseases, including hypertension, diabetes, stroke and particularly coronary heart disease. post stroke depression (psd) may develop as a result of vascular disease. a previous meta-analysis showed that depression significantly increased the risk of development of stroke, and this increase was probably independent of other risk factors, including hypertension and diabetes. clarifying this issue has important implications; if depression increases the risk of development of recurrent stroke, so treating psd might decrease the occurrence of recurrent stroke. to our knowledge there is no study attempting to clarify the relationship between psd treatment and stroke recurrence. to fill these gap, we systematically conducted a study to assess whether psd is associated with recurrent stroke, cardiovascular events or death. thus, in the current study, three different arms of follow-up of patients with first-ever stroke, were used to predict the outcome over 52 weeks.

Eligibility criteria:
inclusion criteria: • patients who met dsm-iv and v criteria for depression exclusion criteria: * severe or unstable medical disorders (eg, myocardial infarction within past 3 months, end-stage cancer, decompensated cardiac failure) * known primary neurological disorders including dementia, delirium, parkinson disease, brain tumors, multiple sclerosis, seizure disorder * drugs (eg, systemic steroids) * pancreatic cancer, uncorrected hypothyroidism * current suicidal risk * use of psychotropic prescription or nonprescription drugs, certain hypnotics * mini-mental state examination (mmse) score of 21 or lower

Keywords: depression treatment stroke myocardial infarction
study to assess adverse events and change in disease activity of 24-hour continuous subcutaneous infusion of abbv-951 in adult participants with advanced parkinson's disease

Conditions: Parkinson's Disease (PD)

Summary: parkinson's disease (pd) is a neurological condition, which affects the brain. pd gets worse over time, but how quickly it progresses varies a lot from person to person. some symptoms of pd are tremors, stiffness, and slowness of movement. this study will assess how safe and effective abbv-951 is in adult participants with pd. adverse events and change in disease activity is evaluated. abbv-951 is an investigational (unapproved) drug containing levodopa phosphate/carbidopa phosphate (ldp/cdp) given as an infusion under the skin for the treatment of parkinson's disease. adult participants with advanced pd and who have completed m15-736 or m20-339 study will be enrolled. approximately 130 participants will be enrolled in the study in approximately 60 sites in the united states and australia. participants will receive continuous subcutaneous infusion (csci) (under the skin) of abbv-951 for 96 weeks during the primary treatment period and during the optional extended treatment period. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the course of the study at a hospital or clinic. the effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.


Eligibility criteria:
inclusion criteria: - completion of the parent study, study m15-736 or study m20-339. exclusion criteria: - participant considered by the investigator to be an unsuitable candidate to receive abbv-951 for any reason.

Keywords: parkinson's disease pd abbv-951 levodopa/carbidopa (ld/cd) levodopa phosphate/carbidopa phosphate (ldp/cdp)
reflectance confocal imaging in cervical cancer patients

Conditions: Cervical Cancer

Summary: the goal of this clinical research study is to see if reflectance confocal microscopy works as well as standard methods to detect cancer of the cervix or precancerous lesions. primary objectives: 1. to identify potential clinical advantages for a noninvasive method of diagnosing dysplasia and neoplasia in the cervix using reflectance confocal microscopy. 2. to obtain real time reflected light images in vivo of sites in the human cervix. 3. to access the effects of acetic acid as a contrast agent for in vivo reflectance confocal imaging. 4. evaluate the depth of penetration for the fiber optic confocal device and analyze the diagnostic value of images taken from different depths. 5. determine the sensitivity and specificity of this device for the diagnosis of cin.

confocal microscopy may be a new way to detect lesions of the cervix quickly without removing a tissue sample. women in the study will already be scheduled for colposcopy to detect or treat cervical lesions. (a colposcopy is an exam of the vagina and cervix using a magnifying lens.) microscopic images will be taken during the routine colposcopy in the outpatient clinic. a disinfected probe will be inserted into the vagina and placed against the cervix. . the probe sends out laser light and detects reflected light from the tissue. images of cervical tissue will be formed and displayed on a computer monitor. 1-3 regions of the cervix will be imaged (2 abnormal and one normal), and each will take about 1-2 minutes. each imaged site will be biopsied. the biopsies will be analyzed by the research pathologist. the results will be available to participants in the event that care needs to be given. total participation in this study will be only a few minutes. this is an investigational study. about 72 women will take part in this study. about 18 will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: * subjects will be individuals 18 years of age or older, who have voluntarily responded to advertisement in the form of posted flyers or word of mouth. * subjects must sign an informed consent indicating awareness of the investigational nature of this study. exclusion criteria: * pregnant individuals will be ineligible for this study.

Keywords: cervical intraepithelial neoplasia cervical cancer reflectance confocal imaging colposcopy
efficacy and safety of diclofenac sodium gel in knee osteoarthritis

Conditions: Osteoarthritis

Summary: this study will test the efficacy and safety of topical diclofenac sodium gel in the treatment of knee osteoarthritis.


Eligibility criteria:
key inclusion criteria * osteoarthritis of the knee key exclusion criteria * other rheumatic disease, such as rheumatoid arthritis * active gastrointestinal ulcer during the last year * known allergy to analgesic drugs

Keywords: knee osteoarthritis, topical nsaid, diclofenac sodium
once-a-day prophylaxis for youth and young adults with severe hemophilia a

Conditions: Hemophilia A

Summary: the primary objective of this study is to test the feasibility of a large-scale clinical trial of once-daily prophylaxis. the secondary objectives are to collect clinical efficacy outcomes so that we can better plan a large-scale study; we will estimate the effect size and variability of effect and resource utilization of once-daily prophylaxis to allow us to set a sample size for a definitive trial.

hemophilia is an important and costly disorder; if left untreated, it may have serious consequences. the greatest impact of hemophilia occurs from recurrent bleeding into joints. the consequences of joint bleeding include pain associated with acute bleeding and later chronic arthropathy. half of affected children with severe hemophilia have joint damage; joint damage is more frequent with increased bleeding. the prevention and treatment of bleeding is very expensive and therefore finding a cost-effective treatment is of high priority. worldwide, two major treatment strategies have been used to prevent arthropathy - on demand therapy and factor prophylaxis. the goal of prophylaxis is to convert the severe to the moderate phenotype by providing circulating factor activity of greater than 1%. patients with greater than 1% circulating factor viii activity rarely have spontaneous hemarthroses. therefore, the goal of providing circulating factor at this level is to eliminate spontaneous hemarthroses. the term primary prophylaxis suggests using preventative factor viii replacement from a very early age. the term secondary prophylaxis is used to describe the application of prophylaxis at a later disease stage. in this study, secondary prophylaxis will be used. once-daily prophylaxis is a novel application of hemophilia factor prophylaxis for youth and young adults. before embarking on a costly definitive trial we feel that it is necessary to demonstrate that subjects will be willing to enroll and will be compliant with the therapy. moreover, we need to establish an estimate of the effect of once-daily prophylaxis on bleeding rates, quality of life, and joint damage progression in order to design a definitive trial.

Eligibility criteria:
inclusion criteria: * severe hemophilia a (\<1% factor viii) * age 12 to 24 years inclusive * male * no current factor viii inhibitor (an inhibitor will be defined as ≥ 0.6 bethesda units) within the past year * able to participate in a home infusion program with adequate peripheral venous access as assessed ny the treating investigator exclusion criteria: * important co-morbidities (acquired immunodeficiency syndrome or symptomatic hiv infection, symptomatic hepatitis b or c infection) * other concomitant acquired or congenital bleeding disorder (e.g. von willebrand's disease) * receiving factor viii replacement through central venous catheter

Keywords: hemophilia prophylaxis youth young adults feasibility
the acute coronary syndrome study

Conditions: Acute Coronary Syndrome

Summary: the investigators will make a prospective study in which they will look at the economics and security of the treatment of patients with acute coronary syndrome. the investigators want to do a randomized trial. one group will be treated as they have been treated at ullevål university hospital (uus) in recent years, and the other group will be returned to their refering hospital the same day. the objective of this study will be to provide increased knowledge about whether the rapid discharge from the intervention center is associated with differences in costs or security.

the topic of this study is whether patients with acute coronary syndrome (acs)may can be transferred to their refering hospital same day that they arrived intervention hospital. this is to see if one can reduce the hospital stay and costs for the intervention center, and the total hospitalization time. and this rapid transport not give more medical complications our 1 hypothesis is that patients with acs, who are transported back to the refering hospital the same day, will reduce the length of stay in intervention center without an increase for the stay at the refering hospital. our 2 hypothesis is that patients with acs, who are transported back to the refering hospital the same day as the treatment is performed, have no more complications than those who stay overnight in the intervention hospital.

Eligibility criteria:
inclusion criteria: * all patients with acute coronary syndrome who are referred from other hospitals exclusion criteria: * patients younger than 18years. * known mental retardation, dementia or harmful use of alcohol or drugs. * allergy or intolerance to asa and / or clopidogrel. * patients who have previously been involved in this study. * acute stemi infarction for less than 72 hours ago.

Keywords: cost analysis safety length of stay randomized controlled trials early discharge
a comparison of aspheric toric intraocular lens (iol) implantation versus aspheric non-toric lens implantation

Conditions: Cataract

Summary: the purpose of this study was to evaluate and compare uncorrected distance visual acuity measurement in pseudophakic subjects with bilateral implantation of an acrysof iq toric intraocular lens (iol) versus bilateral implantation of an acrysof iq iol.


Eligibility criteria:
inclusion criteria: * willing and able to understand and sign an informed consent; * willing and able to attend post-operative examinations per protocol schedule; * in good ocular health, with the exception of cataracts; * age-related cataracts in both eyes that require extraction followed by implantation of an intraocular lens; * pre-operative corneal cylinder of greater than or equal to 0.75 diopter as determined by auto keratometry; * in good ocular health, with the exception of cataracts; * free of diseases/conditions listed in the precautions of the acrysof® toric and acrysof® iq package inserts; * other protocol-defined inclusion criteria may apply. exclusion criteria: * previous corneal surgery; * corneal abnormality that would prevent stable and reliable visual acuity and refractive measures; * planned multiple procedures during cataract/iol implantation surgery; * ocular disease and/or condition that may compromise study results; * ocular trauma, infections or nasolacrimal drainage system malfunction within 3 months of enrolment; * pregnant or planning pregnancy during course of study; * participation in any other investigational study within 30 days prior to enrolment; * other protocol-defined exclusion criteria may apply.

Keywords: intraocular lens toric
real-time noma evaluation

Conditions: Critical Illness

Summary: alerts related to outlier clinician behavior are generated in real-time by an intelligent system continuously scraping ehr (electronic health record) data. these alerts are passed to the bedside and their potential impact on bedside clinical behavior is evaluated.

a clinician-informed ai model will generate outlier alerts from real-time review of the ehr (electronic health record) of upmc presbyterian/montefiore icu patients. these alerts will first be reviewed by an icu clinician, along with the patients' ehr, for clinical relevance. for those alerts deemed potentially relevant, the icu clinician will contact the treating icu clinician (eg, an icu pharmacist, physician, advanced practice provider) and discuss the alert. the treating icu clinician will take whatever action, including no action, they deem best.

Eligibility criteria:
inclusion criteria: * all patients in the presbyterian and montefiore icus exclusion criteria: * none
effect of cp-778,875 on hdl-c in subjects with abnormal lipid levels and type 2 diabetes.

Conditions: Dyslipidemia

Summary: to assess the effect of cp-778,875 on hdl-c cholesterol in adult subjects with dyslipidemia and type 2 diabetes


Eligibility criteria:
inclusion criteria: * hdl-c \< or = 45 mg/dl for men and \< or = 55 mg/dl for women * triglycerides between 150-500 mg/dl * fasting plasma glucose 140-240 mg/dl exclusion criteria: * known cardiovascular, carotid, or peripheral vascular disease
preference of room setting and waiting time in patients with advanced, locally advanced, or metastatic cancer and their caregivers who are seen in the outpatient supportive/palliative care center

Conditions: Advanced Malignant Neoplasm; Caregiver; Locally Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm

Summary: this trial studies the preference of room setting and waiting time in patients with cancer that has spread to nearby tissue or lymph nodes or other places in the body and their caregivers who are seen in the outpatient supportive/palliative care center. room setting preferences of patients and caregivers may help to understand their opinion regarding direct rooming system in the outpatient supportive/palliative care center.

primary objectives: i. to determine patients and caregivers preferences regarding the rooming process in outpatient supportive palliative care clinic, measured by the preference to exam room versus waiting area. secondary objectives: i. patients and caregiver perceptions regarding room setting and waiting time in the outpatient supportive care clinic. ii. extent/experience of team contact in the outpatient supportive care clinic. iii. the factors associated with rooming preferences such as age, gender, symptom distress and performance status. iv. the association between level of distress (physical, psychological, and spiritual distress as measured by edmonton symptom assessment scale (esas) and perception of usefulness of the visit to palliative care center. v. the attitudes and beliefs toward usefulness of referral to outpatient palliative care. vi. the correlation between the patient and caregivers preferences. outline: patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.

Eligibility criteria:
inclusion criteria: * patient: have advanced cancer, defined as locally advanced, metastatic or incurable disease. * patient: seen at university of texas m. d. anderson cancer center (utmdacc) outpatient supportive care center for consultation (first visit). * patient: provided informed consent. * patient: can read and speak english or spanish. * patient: has a consenting caregiver at the time of the supportive care consultation visit. * caregiver: provided informed consent. * caregiver: can read and speak english or spanish. * caregiver: must be with consenting patient at the time of the supportive care consultation visit. exclusion criteria: * patient: delirium diagnosed by palliative care physician or nurse and/or memorial delirium assessment scale (mdas) \>= 7 or dementia. * patient: inability to read and speak english or spanish. * patient: no caregiver at the time of supportive care consultation visit. * caregiver: inability to read and speak english or spanish.
integrating geriatric assessment for older patients diagnosed with acute myelogenous leukemia

Conditions: Acute Myeloid Leukemia

Summary: despite the suggestions that ga and frailty indices could be used to guide therapy selection, the ability to effectively incorporate the use of ga in older patients diagnosed with aml in a real-world clinic environment has not yet been established. thus, in this study, the investigators seek to describe the feasibility of using this shorter ga tool, the mga, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mga results on treatment decision-making.

this outcomes study has a two-part intervention that includes 1) provider education and 2) patient and provider use of carevive treatment care planning technology. the provider education component of the intervention highlights evidenced guidelines and investigational agents in the treatment of aml in older adults. the carevive cps will be used for the second component of the intervention. the results of this study will provide important information about drivers of treatment decision-making and practice patterns, feasibility of a technology platform to incorporate important, but under-utilized components of value-based care into practice, and healthcare utilization data.

Eligibility criteria:
inclusion criteria: * all participants must be adults ages 18 years of age or older. * patient participants must have a diagnosis of aml. * patients may be newly diagnosed, needing a new line of therapy and have not yet made a treatment decision, or on treatment and being assessed for potential new treatment * all participants must be able to understand english. exclusion criteria: * any patient who cannot understand written or spoken english. * any prisoner and/or other vulnerable persons as defined by nih (45 cfr 46, subpart b, c and d).
the effects of lycopene on high risk prostatic tissue

Conditions: Intraepithelial Prostatic Neoplasia; Prostatic Neoplasms

Summary: the purpose of this research study is to compare the effects of a lycopene supplement made from tomatoes to a placebo (a capsule with no active ingredients) in men who have abnormal cells in the prostate, but have not yet had cancer detected. this study will allow us to see if taking lycopene for six months leads to favorable changes in abnormal prostate tissue and in chemicals measured in the blood that go along with a higher risk of developing cancer.


Eligibility criteria:
inclusion criteria: * male * have a history of prostate biopsy indicating hgpin without cancer within 2 years prior to registration. at least 4 weeks must have elapsed between the last biopsy and the biopsy used for baseline data. * have an aua symptom score \<=25 at time of registration. * refrain from taking lycopene, selenium, vitamin e, or other antioxidant supplements within 1 month of randomization. participants must agree to refrain from taking non-study dietary supplements while on study * refrain from taking exogenous hormones, drugs affecting hormone metabolism, or specified non-prescription substances (e.g. saw palmetto, pc-spes) taken to affect the prostate within 1 month of registration. patients must also agree to refrain from taking the non-prescription substances while on study * be willing to limit intake of lycopene-containing foods while on study * have no prior cancer (except basal cell or squamous cell skin cancer) or complete remission for at least 5 years * be ambulatory, capable of self-care and able to carry out light or sedentary work * have a dietary fat intake of 23-48% of calories * participant's physician recommends repeat biopsy 4-6 months after randomization exclusion criteria: * no repeat biopsy planned * not willing to change diet * have a diagnosis of prostate cancer

Keywords: intraepithelial prostatic neoplasia prostatic neoplasms male urogenital disease prostate
childhood asthma and schooling: the truth unveiled

Conditions: Bronchial Asthma

Summary: childhood asthma and schooling: the truth unveiled.

children with mild persistent asthma still performed worse than normal healthy children in school. the aim of the study was to evaluate school performance of children with mild persistent asthma in comparison with normal healthy children.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of bronchial asthma * must be able to swallow tablets exclusion criteria: * steroid inhalation or ingestion

Keywords: the effect of bronchial asthma on school performance
ticagrelor versus clopidogrel for cmd in patients with ami: a retrospective study based on the angio-imr

Conditions: Coronary Heart Disease

Summary: coronary microvascular dysfunction (cmd) is increasingly recognized as an important indicator for long-term prognosis in patients with acute myocardial infarction (ami). the angiography-derived index of microcirculatory resistance (angio-imr) is a novel guidewire-free measure for cmd in patients with ami. ticagrelor has recently been suggested to have additional benefits on coronary microcirculation beyond its antiplatelet effect. this study was designed to compare the protective effects of ticagrelor and clopidogrel on cmd and prognostic impact in patients with ami, using the angio-imr as a novel assessment tool.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed with ami, including stemi and nstemi, and underwent successful pci and routine follow-up coronary angiography at the second affiliated hospital of zhejiang university school of medicine between june 1, 2017 and may 31, 2020. exclusion criteria: * 1) prior treatment with any p2y12 inhibitor; * 2) need for long-term oral anticoagulation therapy; * 3) previous coronary artery bypass grafting (cabg); * 4) chronic renal dysfunction with estimated glomerular filtration rate (egfr) \<30 ml/ (min·1.73 m2) or on hemodialysis; * 5) liver cirrhosis ≥child-pugh b class; * 6) cancer; * 7) adjustment of dual antiplatelet therapy (dapt) during follow-up; * 8) inadequate coronary angiographic images.